A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer
Neoadjuvant chemotherapy aims to improve the outcome of breast cancer patients, but only few would benefit from this treatment. Pathological complete response has been proposed as a surrogate marker for the prediction of long-term clinical benefits; however, 50%–85% patients have an unfavorable path...
Saved in:
Main Authors: | Raúl García-Vazquez, Erika Ruiz-García, Abelardo Meneses García, Horacio Astudillo-de la Vega, Fernando Lara-Medina, Alberto Alvarado-Miranda, Héctor Maldonado-Martínez, Juan A González-Barrios, Alma D Campos-Parra, Sergio Rodríguez Cuevas, Laurence A Marchat, César López-Camarillo |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2017-05-01
|
Series: | Tumor Biology |
Online Access: | https://doi.org/10.1177/1010428317702899 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
COMPARATIVE ANALYSIS OF DIFFERENT NEOADJUVANT CHEMOTHERAPY REGIMENS FOR TRIPLE-NEGATIVE BREAST CANCER
by: P. V. Krivorotko, et al.
Published: (2017-12-01) -
Efficacy and safety of cisplatin and paclitaxel (PlaTax regimen) in the neoadjuvant treatment of patients with stage II–III triple-negative breast cancer
by: O. O. Gordeeva, et al.
Published: (2020-11-01) -
MicroRNA Target Signatures in Advanced Stage Neuroblastoma
by: Chu, Victoria R., et al.
Published: (2012) -
Regulatory Genetic Networks by microRNAs: Exploring Genomic Signatures in Cervical Cancer
by: Carlos Pérez-Plasencia, et al.
Published: (2025-06-01) -
DNA Repair in Pathogenic Eukaryotic Cells: Insights from Comparative Genomics of Parasitic Protozoan
by: Marchat, Laurence A., et al.
Published: (2011)